170 related articles for article (PubMed ID: 20230864)
1. The in vitro and in vivo evaluation of new synthesized prodrugs of 5-OH-DPAT for iontophoretic delivery.
Ackaert OW; De Graan J; Capancioni R; Della Pasqua OE; Dijkstra D; Westerink BH; Danhof M; Bouwstra JA
J Control Release; 2010 Jun; 144(3):296-305. PubMed ID: 20230864
[TBL] [Abstract][Full Text] [Related]
2. Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro.
Nugroho AK; Li L; Dijkstra D; Wikström H; Danhof M; Bouwstra JA
J Control Release; 2005 Mar; 103(2):393-403. PubMed ID: 15763622
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic studies of the transdermal iontophoretic delivery of 5-OH-DPAT in vitro.
Ackaert OW; Van Smeden J; De Graan J; Dijkstra D; Danhof M; Bouwstra JA
J Pharm Sci; 2010 Jan; 99(1):275-85. PubMed ID: 19718740
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and pharmacological effect of (S)-5-OH-DPAT following controlled delivery with transdermal iontophoresis.
Ackaert OW; De Graan J; Shi S; Vreeken R; Pasqua OE; Dijkstra D; Westerink BH; Danhof M; Bouwstra JA
J Pharm Sci; 2011 Jul; 100(7):2996-3009. PubMed ID: 21283984
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation.
Nugroho AK; Romeijn SG; Zwier R; de Vries JB; Dijkstra D; Wikström H; Della-Pasqua O; Danhof M; Bouwstra JA
J Pharm Sci; 2006 Jul; 95(7):1570-85. PubMed ID: 16732562
[TBL] [Abstract][Full Text] [Related]
6. Combined effects of iontophoretic and chemical enhancement on drug delivery. II. Transport across human and murine skin.
Nolan LM; Corish J; Corrigan OI; Fitzpatrick D
Int J Pharm; 2007 Aug; 341(1-2):114-24. PubMed ID: 17502130
[TBL] [Abstract][Full Text] [Related]
7. The acute and chronic administration of (+/-)-8-hydroxy-2-(Di-n-propylamino)tetralin significantly alters the activity of spontaneously active midbrain dopamine neurons in rats: an in vivo electrophysiological study.
Nakamura K; Suzuki K; McCreary AC; Ashby CR
Synapse; 2006 May; 59(6):359-67. PubMed ID: 16463399
[TBL] [Abstract][Full Text] [Related]
8. Skin permeation and ex vivo skin metabolism of O-acyl haloperidol ester prodrugs.
Morris AP; Brain KR; Heard CM
Int J Pharm; 2009 Feb; 367(1-2):44-50. PubMed ID: 18845232
[TBL] [Abstract][Full Text] [Related]
9. A duplex "Gemini" prodrug of naltrexone for transdermal delivery.
Hammell DC; Hamad M; Vaddi HK; Crooks PA; Stinchcomb AL
J Control Release; 2004 Jun; 97(2):283-90. PubMed ID: 15196755
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of quercetin-3-O-acyl esters as topical prodrugs.
Montenegro L; Carbone C; Maniscalco C; Lambusta D; Nicolosi G; Ventura CA; Puglisi G
Int J Pharm; 2007 May; 336(2):257-62. PubMed ID: 17257788
[TBL] [Abstract][Full Text] [Related]
11. Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: effect of experimental conditions and a comparison with other enhancement strategies.
Cázares-Delgadillo J; Ganem-Rondero A; Quintanar-Guerrero D; López-Castellano AC; Merino V; Kalia YN
Eur J Pharm Sci; 2010 Mar; 39(5):387-93. PubMed ID: 20096354
[TBL] [Abstract][Full Text] [Related]
12. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs.
Yang JZ; Chen W; Borchardt RT
J Pharmacol Exp Ther; 2002 Nov; 303(2):840-8. PubMed ID: 12388671
[TBL] [Abstract][Full Text] [Related]
13. Ketorolac amide prodrugs for transdermal delivery: stability and in vitro rat skin permeation studies.
Kim BY; Doh HJ; Le TN; Cho WJ; Yong CS; Choi HG; Kim JS; Lee CH; Kim DD
Int J Pharm; 2005 Apr; 293(1-2):193-202. PubMed ID: 15778057
[TBL] [Abstract][Full Text] [Related]
14. Ester prodrugs of morphine improve transdermal drug delivery: a mechanistic study.
Wang JJ; Sung KC; Huang JF; Yeh CH; Fang JY
J Pharm Pharmacol; 2007 Jul; 59(7):917-25. PubMed ID: 17637185
[TBL] [Abstract][Full Text] [Related]
15. Stereoselectivity of 8-OH-DPAT toward the serotonin 5-HT1A receptor: biochemical and molecular modeling study.
Dabrowska J; Brylinski M
Biochem Pharmacol; 2006 Aug; 72(4):498-511. PubMed ID: 16796994
[TBL] [Abstract][Full Text] [Related]
16. (R)- and (S)-5-hydroxy-2-(dipropylamino)tetralin (5-OH DPAT): assessment of optical purities and dopaminergic activities.
Karlsson A; Björk L; Pettersson C; Andén NE; Hacksell U
Chirality; 1990; 2(2):90-5. PubMed ID: 1976017
[TBL] [Abstract][Full Text] [Related]
17. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
18. 5-HT1a agonist +/-8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine.
Rasmusson AM; Goldstein LE; Deutch AY; Bunney BS; Roth RH
Synapse; 1994 Nov; 18(3):218-24. PubMed ID: 7855734
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
[TBL] [Abstract][Full Text] [Related]
20. 5-hydroxytryptamine (5-HT)1A receptors and the tail-flick response. I. 8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks in the rat as an in vivo model of 5-HT1A receptor-mediated activity.
Millan MJ; Bervoets K; Colpaert FC
J Pharmacol Exp Ther; 1991 Mar; 256(3):973-82. PubMed ID: 1826033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
